9 results on '"Chin Hui Ng"'
Search Results
2. Estimating the Costs of Managing Complications of Type 2 Diabetes Mellitus in Malaysia
- Author
-
Chin Hui Ng and Asrul Akmal Shafie
- Subjects
03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030503 health policy & services ,medicine ,Type 2 Diabetes Mellitus ,030212 general & internal medicine ,0305 other medical science ,Intensive care medicine ,business ,health care economics and organizations - Abstract
This study aimed to estimate current direct costs for managing type 2 diabetes mellitus (T2DM)-related complications including ischaemic heart diseases (IHD), myocardial infarction (MI), stroke, heart failure (HF), amputation, blindness, renal failure (RF) requiring haemodialysis (end-stage renal disease) and diabetic foot ulcer in the event year and subsequent year. Initially, diabetes-related complications are defined based on the Malaysian Clinical Practice Guidelines (CPGs) or published literatures while each resource unit was valued using local costing obtained from the public hospital or other sources. The interventions for the management of complications were supported by evidence in the Malaysian CPGs or local literature and confirmed by the physicians related to the field who are working at the public hospital. All costs were converted to the value of USD currency in the year 2016. On the whole, macrovascular diseases incurred the highest management cost with MI employing the highest management cost (USD4,528.37) in the event year, while the management of heart, failure disease incurs the highest management cost at USD524.79 for subsequent year management. End-stage renal disease was associated with the highest annual per-patient costs, with mean first year and subsequent year costs for haemodialysis estimated at USD9,905.37 and USD9,233.89. In studying the costs of managing of diabetes-related complications, these data are vital economic evaluation for diabetes interventions, particularly in managing complications to macrovascular and microvascular functions, as it contributes significantly to the economic burden in Malaysia’s public healthcare; hence significantly affecting the proportion of the overall healthcare costs.
- Published
- 2020
3. Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
- Author
-
Asrul Akmal Shafie and Chin Hui Ng
- Subjects
Oncology ,medicine.medical_specialty ,endocrine system diseases ,type 2 diabetes mellitus ,Cost effectiveness ,medicine.medical_treatment ,Economics, Econometrics and Finance (miscellaneous) ,NPH insulin ,Hypoglycemia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,medicine ,030212 general & internal medicine ,health care economics and organizations ,Original Research ,Insulin detemir ,Insulin glargine ,business.industry ,030503 health policy & services ,Health Policy ,Insulin ,insulin Detemir ,cost-effectiveness analysis ,nutritional and metabolic diseases ,insulin Glargine ,medicine.disease ,Basal (medicine) ,0305 other medical science ,business ,medicine.drug - Abstract
Objective To compare the cost-effectiveness of long-acting insulin analogue (LAIA) (insulin Detemir and insulin Glargine) versus NPH insulin in the basal insulin regime for naive insulin T2DM Malaysian patients. Methods The UKPDS-Outcome Model version 2.0 (UKPDS-OM2) was used to evaluate the cost and consequence of diabetes-related complication. The effectiveness of the insulin was derived from the literature review, and the patients' epidemiology characteristics were retrieved from the Malaysian Diabetes Registry. A discount rate of 3% was applied to both costs and health effects. Another simple mathematical model was used to compare the benefit of reducing the hypoglycemia events between LAIA and NPH insulin. The outputs of the models were combined to obtain the final result. One-way sensitivity analyses were performed to assess the uncertainties. Results The net cost difference (without accounting for hypoglycemia) was RM4868 for insulin Glargine and RM6026 for insulin Detemir. The saving from preventing severe hypoglycemia was RM4377 for insulin Glargine and RM12,753 for insulin Detemir. The total additional QALY gained from insulin Glargine was 0.1317 and from insulin Detemir was 0.8376. The sensitivity analysis shows the discount rate, and drug acquisition cost may affect the incremental cost-effectiveness ratio (ICER) value. Conclusion Both insulin Detemir and Glargine are cost-effective compared to NPH insulin for T2DM patients, especially when the benefit of reducing the hypoglycemia event rate is taken into account.
- Published
- 2020
4. Systematic review of economic burden of heart failure
- Author
-
Chin Hui Ng, Yui Ping Tan, and Asrul Akmal Shafie
- Subjects
Heart Failure ,medicine.medical_specialty ,Cost estimate ,business.industry ,Health Care Costs ,CINAHL ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Cost of Illness ,Cost driver ,Heart failure ,Emergency medicine ,Epidemiology ,Humans ,Medicine ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,Activity-based costing ,business ,Unit cost ,health care economics and organizations ,Valuation (finance) - Abstract
The aim of this study is to perform a systematic review of the costing methodological approaches adopted by published cost-of-illness (COI) studies. A systematic review was performed to identify cost-of-illness studies of heart failure published between January 2003 and September 2015 via computerized databases such as Pubmed, Wiley Online, Science Direct, Web of Science, and Cumulative Index to Nursing and Allied Health Literature (CINAHL). Costs reported in the original studies were converted to 2014 international dollars (Int$). Thirty five out of 4972 studies met the inclusion criteria. Nineteen out of the 35 studies reported the costs as annual cost per patient, ranging from Int$ 908.00 to Int$ 84,434.00, while nine studies reported costs as per hospitalization, ranging from Int$ 3780.00 to Int$ 34,233.00. Cost of heart failure increased as condition of heart failure worsened from New York Heart Association (NYHA) class I to NYHA class IV. Hospitalization cost was found to be the main cost driver to the total health care cost. The annual cost of heart failure ranges from Int$ 908 to Int$ 40,971 per patient. The reported cost estimates were inconsistent across the COI studies, mainly due to the variation in term of methodological approaches such as disease definition, epidemiological approach of study, study perspective, cost disaggregation, estimation of resource utilization, valuation of unit cost components, and data sources used. Such variation will affect the reliability, consistency, validity, and relevance of the cost estimates across studies.
- Published
- 2017
5. Estimating the utility value of hypoglycaemia according to severity and frequency using the visual analogue scale (VAS) and time trade-off (TTO) survey
- Author
-
Asrul Akmal Shafie, Norliza Haron, Subramaniam Thanimalai, Anita Bhajan Manocha, and Chin Hui Ng
- Subjects
Pediatrics ,medicine.medical_specialty ,Health utility ,endocrine system diseases ,Visual analogue scale ,Endocrinology, Diabetes and Metabolism ,Population ,030209 endocrinology & metabolism ,macromolecular substances ,Time-trade-off ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal Medicine ,Medicine ,In patient ,030212 general & internal medicine ,education ,education.field_of_study ,business.industry ,Type 2 Diabetes Mellitus ,nutritional and metabolic diseases ,medicine.disease ,Health states ,business ,hormones, hormone substitutes, and hormone antagonists ,Research Article - Abstract
OBJECTIVES: The primary objective of this study was to estimate the health utility values for hypoglycaemia events according to their severity and frequency. The secondary objective was to compare the health utilities between those with Type 2 Diabetes Mellitus and the general population. METHOD: The health utilities of hypoglycaemia event were measured using Visual Analogue Scale (VAS) and Time Trade-Off (TTO) methods among conveniently sampled consenting adults (>18 years and literate in either English or Malay language), which were then divided into two groups: those in the general population (GP) and those with Type 2 Diabetes Mellitus (T2DM). Each respondent was required to value 13 different health states, including frequencies of daytime hypoglycaemia and nocturnal hypoglycaemia, each depending on its severity (non-severe or severe). RESULTS: 256 respondents from the GP and 99 respondents with T2DM completed the survey. The T2DM group gave higher VAS-values compared to the GP group. The highest mean VAS-utility value for non-severe nocturnal hypoglycaemia occurring once monthly was 0.543 (SD 0.161), and for severe daytime hypoglycaemia occurring once quarterly was 0.293 (SD 0.162) which was the lowest utility value compared to other health states. However, non-severe nocturnal hypoglycaemia occurring once quarterly was 0.537 (SD 0.284) and has the highest TTO-utility value. Severe nocturnal hypoglycaemia occurring once quarterly has the lowest utility value which was −0.104 (SD 0.380). Daytime hypoglycaemia has lower utility value compared to nocturnal hypoglycaemia. Severe hypoglycaemia has a greater disutility compared with the non-severe hypoglycaemia in both studied groups. CONCLUSION: The findings show that as a health utility, hypoglycaemia has a substantial impact on utility with severe hypoglycaemia having a greater negative impact compared to non-severe events across the board. This highlights the importance of preventing development of severe hypoglycaemia in patients with Type 2 Diabetes Mellitus at any time of the day.
- Published
- 2018
6. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
- Author
-
Asrul Akmal Shafie, Yui Ping Tan, Nathorn Chaiyakunapruk, and Chin Hui Ng
- Subjects
Canada ,medicine.medical_specialty ,endocrine system diseases ,Cost effectiveness ,Cost-Benefit Analysis ,medicine.medical_treatment ,Insulins ,030209 endocrinology & metabolism ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Hypoglycemic Agents ,030212 general & internal medicine ,Glycated haemoglobin ,Glycated Hemoglobin ,Pharmacology ,Type 1 diabetes ,business.industry ,Health Policy ,Insulin ,Public Health, Environmental and Occupational Health ,Type 2 Diabetes Mellitus ,medicine.disease ,Quality-adjusted life year ,Diabetes Mellitus, Type 1 ,Endocrinology ,Diabetes Mellitus, Type 2 ,Delayed-Action Preparations ,Economic evaluation ,Quality-Adjusted Life Years ,business - Abstract
Insulin analogues have a pharmacokinetic advantage over human insulin and are increasingly used to treat diabetes mellitus. A summary of their cost effectiveness versus other available treatments was required. Our objective was to systematically review the published cost-effectiveness studies of insulin analogues for the treatment of patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). We searched major databases and health technology assessment agency reports for economic evaluation studies published up until 30 September 2015. Two reviewers performed data extraction and assessed the quality of the data using the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) guidelines. Seven of the included studies assessed short-acting insulin analogues, 12 assessed biphasic insulin analogues, 30 assessed long-acting insulin analogues and one assessed a combination of short- and long-acting insulin analogues. Only 17 studies involved patients with T1DM, all were modelling studies and 12 were conducted in Canada. The incremental cost-effectiveness ratios (ICERs) for short-acting insulin analogues ranged from dominant to $US435,913 per quality-adjusted life-year (QALY) gained, the ICERs for biphasic insulin analogues ranged from dominant to $US57,636 per QALY gained and the ICERs for long-acting insulin analogues ranged from dominant to $US599,863 per QALY gained. A total of 15 studies met all the CHEERS guidelines reporting quality criteria. Only 26 % of the studies assessed heterogeneity in their analyses. Current evidence indicates that insulin analogues are cost effective for T1DM; however, evidence for their use in T2DM is not convincing. Additional evidence regarding compliance and efficacy is required to support the broader use of long-acting and biphasic insulin analogues in T2DM. The value of insulin analogues depends strongly on reductions in hypoglycaemia event rates and its efficacy in lowering glycated haemoglobin (HbA1c).
- Published
- 2016
7. ESTIMATING THE COSTS OF MANAGING COMPLICATIONS OF TYPE 2 DIABETES MELLITUS IN MALAYSIA.
- Author
-
SHAFIE, ASRUL AKMAL and CHIN HUI NG
- Subjects
TYPE 2 diabetes ,COST estimates ,DIABETIC foot ,MYOCARDIAL infarction ,CHRONIC kidney failure ,FOOT care - Abstract
This study aimed to estimate current direct costs for managing type 2 diabetes mellitus (T2DM)-related complications including ischaemic heart diseases (IHD), myocardial infarction (MI), stroke, heart failure (HF), amputation, blindness, renal failure (RF) requiring haemodialysis (end-stage renal disease) and diabetic foot ulcer in the event year and subsequent year. Initially, diabetes-related complications are defined based on the Malaysian Clinical Practice Guidelines (CPGs) or published literatures while each resource unit was valued using local costing obtained from the public hospital or other sources. The interventions for the management of complications were supported by evidence in the Malaysian CPGs or local literature and confirmed by the physicians related to the field who are working at the public hospital. All costs were converted to the value of USD currency in the year 2016. On the whole, macrovascular diseases incurred the highest management cost with MI employing the highest management cost (USD4,528.37) in the event year, while the management of heart, failure disease incurs the highest management cost at USD524.79 for subsequent year management. End-stage renal disease was associated with the highest annual per-patient costs, with mean first year and subsequent year costs for haemodialysis estimated at USD9,905.37 and USD9,233.89. In studying the costs of managing of diabetes-related complications, these data are vital economic evaluation for diabetes interventions, particularly in managing complications to macrovascular and microvascular functions, as it contributes significantly to the economic burden in Malaysia's public healthcare; hence significantly affecting the proportion of the overall healthcare costs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Estimating the utility value of hypoglycaemia according to severity and frequency using the visual analogue scale (VAS) and time trade-off (TTO) survey.
- Author
-
Shafie, Asrul Akmal, Chin Hui Ng, Thanimalai, Subramaniam, Haron, Norliza, and Manocha, Anita Bhajan
- Subjects
- *
HYPOGLYCEMIA , *VISUAL analog scale - Abstract
Objectives The primary objective of this study was to estimate the health utility values for hypoglycaemia events according to their severity and frequency. The secondary objective was to compare the health utilities between those with Type 2 Diabetes Mellitus and the general population. Method The health utilities of hypoglycaemia event were measured using Visual Analogue Scale (VAS) and Time Trade-Off (TTO) methods among conveniently sampled consenting adults (>18 years and literate in either English or Malay language), which were then divided into two groups: those in the general population (GP) and those with Type 2 Diabetes Mellitus (T2DM). Each respondent was required to value 13 different health states, including frequencies of daytime hypoglycaemia and nocturnal hypoglycaemia, each depending on its severity (non-severe or severe). Results: 256 respondents from the GP and 99 respondents with T2DMcompleted the survey. The T2DMgroup gave higher VASvalues compared to the GP group. The highest mean VAS-utility value for non-severe nocturnal hypoglycaemia occurring once monthly was 0.543 (SD 0.161), and for severe daytime hypoglycaemia occurring once quarterly was 0.293 (SD 0.162) which was the lowest utility value compared to other health states. However, non-severe nocturnal hypoglycaemia occurring once quarterlywas 0.537 (SD 0.284) and has the highest TTO-utility value. Severe nocturnal hypoglycaemia occurring once quarterly has the lowest utility value which was -0.104 (SD 0.380). Daytime hypoglycaemia has lower utility value compared to nocturnal hypoglycaemia. Severe hypoglycaemia has a greater disutility compared with the non-severe hypoglycaemia in both studied groups. Conclusion: The findings show that as a health utility, hypoglycaemia has a substantial impact on utility with severe hypoglycaemia having a greater negative impact compared to non-severe events across the board. This highlights the importance of preventing development of severe hypoglycaemia in patients with Type 2 Diabetes Mellitus at any time of the day. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Systematic Review of Cost-Effectiveness Models in Diabetes for Insulin Analogues
- Author
-
Yui Ping Tan, Nathorn Chaiyakunapruk, A.A. Shafie, and Chin Hui Ng
- Subjects
medicine.medical_specialty ,business.industry ,Cost effectiveness ,Health Policy ,Insulin ,medicine.medical_treatment ,Diabetes mellitus ,Public Health, Environmental and Occupational Health ,Medicine ,business ,Intensive care medicine ,medicine.disease - Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.